Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 3;2(6):6.
doi: 10.3389/fendo.2011.00006.

Pharmacoperone identification for therapeutic rescue of misfolded mutant proteins

Affiliations

Pharmacoperone identification for therapeutic rescue of misfolded mutant proteins

P Michael Conn et al. Front Endocrinol (Lausanne). .

Abstract

G protein-coupled receptors (GPCRs), which includes the gonadotropin releasing hormone (GnRH) receptor (GnRHR), comprises the largest family of validated drug targets-more than half of all approved drugs derive their benefits by selective targeting of GPCRs. Most drugs in this class are either agonists or antagonists of GPCRs and high throughput screens (HTSs) have typically been designed and performed with a view toward identification of such compounds as lead drug candidates. This manuscript presents the case that valuable drugs which effect the trafficking of GPCRs may have been overlooked because pharmacoperones have been selected from existing screens that identify agonists and antagonists. A "gain of activity assay" is proposed; this assay relies on the expression of a mutant of the GnRHR that is known to be rescuable by pharmacoperone drugs, and which is restored to activity in their presence. Accordingly, "hits" are identified by the appearance of activity. The gene for the mutant is under control of tetracycline and may be prevented from being expressed. This is a valuable feature since it allows false positives to be identified. Such drugs will show apparent activity whether or not the mutant is expressed. This assay will enable identification of these drugs from chemical libraries and does not rely on their activity as agonists or antagonists.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tetracycline inhibits accumulation of E90K mRNA (normalized with 18S RNA) and assessed by real-time PCR.
Figure 2
Figure 2
Loss of IP production (in the presence of tetracycline) in stably transfected cells with or without In3 treatment shows that expression of the (rescued) mutant protein is under control of this antibiotic.
Figure 3
Figure 3
Well-by-well IP stimulation in response to a GnRH agonist, following rescue of mutant E90K by maximum, EC80, or no pharmacoperone (In3). Data is graphed by row, then column. The upper graphic shows the absence of tetracycline; the lower graphic shows the presence of tetracycline. Note that the y-axis differs.
Figure 4
Figure 4
The same data as in Figure 3, but re-graphed by column, then row in order to reveal any “edge” effects or other artifacts due to the plate.

Similar articles

Cited by

References

    1. Amaral M. D. (2006). Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease. J. Inherit. Metab. Dis. 29, 477–487 - PubMed
    1. Andersson H., D'Antona A. M., Kendall D. A., Von Heijne G., Chin C. N. (2003). Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol. Pharmacol. 64, 570–577 - PubMed
    1. Ashton W. T., Sisco R. M., Kieczykowski G. R., Yang Y. T., Yudkovitz J. B., Cui J., Mount G. R., Ren R. N., Wu T. J., Shen X., Lyons K. A., Mao A. H., Carlin J. R., Karanam B. V., Vincent S. H., Cheng K., Goulet M. T. (2001). Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. Bioorg. Med. Chem. Lett. 11, 2597–2602 - PubMed
    1. Bellotti V., Nuvolone M., Giorgetti S., Obici L., Palladini G., Russo P., Lavatelli F., Perfetti V., Merlini G. (2007). The workings of the amyloid diseases. Ann. Med. 39, 200–207 - PubMed
    1. Benedek G. B., Pande J., Thurston G. M., Clark J. I. (1999). Theoretical and experimental basis for the inhibition of cataract. Prog. Retin. Eye Res. 18, 391–402 - PubMed

LinkOut - more resources